/PRNewswire/ - LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project.
SiteOne Therapeutics begins trial of non-opioid analgesic for acute pain 21 Apr 2021 (Last Updated April 21st, 2021 12:19)
SiteOne Therapeutics has initiated dosing in Phase I study of its experimental intravenous, non-opioid analgesic, ST-2427, for managing moderate to severe pain.
Share Article
The trial is enrolling participants at AltaSciences in Overland Park, Kansas. Credit: fernando zhiminaicela from Pixabay.
SiteOne Therapeutics has initiated dosing in Phase I study of its experimental intravenous, non-opioid analgesic, ST-2427, for managing moderate to severe pain.
ST-2427 is a highly selective inhibitor of sodium ion channel 1.7 (NaV1.7) that is highly expressed in peripheral nerve fibres. It is established as a target for pain treatment by human genetics.
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced that dosing has commenced in the company s Phase 1, dose-escalation study of ST-2427, a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain. The initiation of this study represents a significant milestone for the company as it is our first drug candidate to enter the clinic, stated John Mulcahy, Ph.D., chief executive officer of SiteOne
. There is an urgent, unmet need to develop effective non-opioid therapies for pain. Our lead compound, ST-2427, addresses that need by targeting the peripheral nerve fibers that conduct pain signals without the potential for CNS side effects, addiction and abuse liability of opioid medications.